Our study indicates that FLT3-ITD mut AML patients with hyperleukocytosis could particularly benefit from LA, or that the hyperleukocytosis in these patients may be less damaging to vital organs, resulting in lower early mortality rates. This evidence concerns the gene FLT3 and acute myeloid leukemia.